Attached files
| file | filename |
|---|---|
| 10-K - ANNUAL REPORT - Protara Therapeutics, Inc. | f10k2020_protaratherapeutics.htm |
| EX-31.2 - CERTIFICATION - Protara Therapeutics, Inc. | f10k2020ex31-2_protara.htm |
| EX-31.1 - CERTIFICATION - Protara Therapeutics, Inc. | f10k2020ex31-1_protara.htm |
| EX-23.1 - CONSENT OF MARCUM LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - Protara Therapeutics, Inc. | f10k2020ex23-1_protara.htm |
| EX-21.1 - LIST OF SUBSIDIARIES - Protara Therapeutics, Inc. | f10k2020ex21-1_protara.htm |
| EX-10.25 - LEASE BY AND BETWEEN 345 PAS HOLDING LLC, AND THE REGISTRANT, DATED AS OF DECEMB - Protara Therapeutics, Inc. | f10k2020ex10-25_protara.htm |
| EX-4.2 - DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT OF 193 - Protara Therapeutics, Inc. | f10k2020ex4-2_protara.htm |
Exhibit 32.1
Certification Pursuant to 18 U.S.C.
Section 1350
(as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002)
In connection with this annual report of Protara Therapeutics, Inc. (the “Company”) on Form 10−K for the year ending December 31, 2020, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), we, Jesse Shefferman, Chief Executive Officer of the Company, and Blaine Davis, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes−Oxley Act of 2002, that, to our knowledge:
1. The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| Date: March 11, 2021 | |
| /s/ Jesse Shefferman | |
| Jesse Shefferman | |
| Chief Executive Officer | |
| Date: March 11, 2021 | |
| /s/ Blaine Davis | |
| Blaine Davis | |
| Chief Financial Officer |
This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Protara Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.